PMID- 11872075
OWN - NLM
STAT- MEDLINE
DCOM- 20020308
LR  - 20190910
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 67
IP  - 5-6
DP  - 2001 Nov-Dec
TI  - Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the 
      number of involved anatomic sites.
PG  - 279-88
AB  - BACKGROUND: Advanced Hodgkin's lymphoma (HL) is curable by conventional 
      chemotherapy in 60--70% of patients. The pretreatment identification of a 
      sizeable subgroup of patients with sufficiently low failure-free survival (FFS) 
      to be eligible for investigational treatment is necessary. OBJECTIVES: To 
      determine the prognostic significance of the number of involved sites (NIS) in 
      patients with advanced HL and its relationship to the International Prognostic 
      Score (IPS). METHODS: A retrospective review of patients with advanced HL, 
      defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with 
      anthracycline-based regimens. The end-point was FFS. RESULTS: We identified 277 
      patients with a median age of 32 yr (14--78), 57% of whom were males. AAS was I 
      in 4% of patients, II in 29%, III in 38% and IV in 29%. B-symptoms were recorded 
      in 81%. Most patients had nodular sclerosis (64%) and mixed cellularity (26%) 
      histology. IPS was greater-than-or-equals 3 in 44% of 242 evaluable patients. The 
      NIS was greater-than-or-equals 5 in 32% of the patients and 20% of all patients 
      had both greater-than-or-equals 5 involved sites and IPS greater-than-or-equals 
      3. The 10-yr FFS was 67%, being 76% vs. 50% for patients with less-than-or-equals 
      4 vs. greater-than-or-equals 5 involved sites (P < 0.0001). The NIS 
      (greater-than-or-equal 5), AAS IV and anemia were independent predictors of FFS 
      in multivariate analysis. The NIS remained significant along with IPS, when the 
      latter was included in the analysis. Patients with greater-than-or-equals 5 
      involved sites and IPS greater-than-or-equals 3 had 10-yr FFS overall, and 
      relapse-free survival of 41%, 45% and 49%, respectively. CONCLUSIONS: The NIS was 
      associated with FFS in advanced HL, was independent of IPS, and led to the 
      identification of a sizeable subgroup of patients with 10-yr FFS of approximately 
      40%. This factor should be evaluated during the development of prognostic 
      systems.
FAU - Vassilakopoulos, T P
AU  - Vassilakopoulos TP
AD  - Hematology Section, First Department of Internal Medicine, National and 
      Kapodistrian University, School of Medicine, Laikon General Hospital, Athens, 
      Greece.
FAU - Angelopoulou, M K
AU  - Angelopoulou MK
FAU - Siakantaris, M P
AU  - Siakantaris MP
FAU - Kontopidou, F N
AU  - Kontopidou FN
FAU - Dimopoulou, M N
AU  - Dimopoulou MN
FAU - Barbounis, A
AU  - Barbounis A
FAU - Grigorakis, V
AU  - Grigorakis V
FAU - Karkantaris, C
AU  - Karkantaris C
FAU - Anargyrou, K
AU  - Anargyrou K
FAU - Chatziioannou, M
AU  - Chatziioannou M
FAU - Rombos, J
AU  - Rombos J
FAU - Boussiotis, V A
AU  - Boussiotis VA
FAU - Vaiopoulos, G
AU  - Vaiopoulos G
FAU - Kittas, C
AU  - Kittas C
FAU - Pangalis, G A
AU  - Pangalis GA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Antibiotics, Antineoplastic)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Hodgkin Disease/drug therapy/*pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
EDAT- 2002/03/02 10:00
MHDA- 2002/03/09 10:01
CRDT- 2002/03/02 10:00
PHST- 2002/03/02 10:00 [pubmed]
PHST- 2002/03/09 10:01 [medline]
PHST- 2002/03/02 10:00 [entrez]
AID - 561 [pii]
AID - 10.1034/j.1600-0609.2001.00561.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2001 Nov-Dec;67(5-6):279-88. doi: 
      10.1034/j.1600-0609.2001.00561.x.